Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with myelofibrosis, a rare and aggressive blood cancer.
JAK inhibitor combo therapy shows promise for myelofibrosis treatment in phase 3 trial
